Ozanimod

WEST PALM BEACH, Fla. — In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024.

LAS VEGAS —A presenter at the Crohn’s & Colitis Congress outlined some of the newer therapies that have expanded the current “arsenal of tools” for the treatment of inflammatory bowel disease.

Following 1 year of treatment with ozanimod, individuals with relapsing forms of multiple sclerosis saw functional and cognitive improvements as well as a reduction in MRI lesions, according to interim data presented at ECTRIMS 2023.

Those with relapsing forms of multiple sclerosis treated with ozanimod saw relapse-associated worsening and progression-independent relapse activity contributed similarly to disability progression, according to research from ECTRIMS 2023.

The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active ulcerative colitis, according to a company press release.

SAN DIEGO — Minimal long-term cardiac safety findings were reported with ozanimod treatment in patients with ulcerative colitis and relapsing multiple sclerosis, according to research presented at Digestive Disease Week 2022.

LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs. adalimumab and a comparable profile for ozanimod vs. vedolizumab.

In this exclusive video, William Sandborn, MD, from the University of California, San Diego, discusses research presented at UEG Week Virtual that explored the safety and efficacy of Zeposia in ulcerative colitis.